RET

(redirected from Receptor tyrosine kinase)
Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

Ret

(ret),
Oncogene product defective in multiple endocrine neoplasia types IIA and IIB and Hirschsprung disease. It belongs to that class of membrane receptors with tyrosine kinase activity.

RET

abbreviation for rational emotive therapy.

RET

A gene on chromosome 10q11.2 that encodes a receptor for tyrosine-protein kinase involved in various cellular processes, including cell proliferation and migration, neuronal navigation and cell differentiation, upon binding with glial-cell-derived neurotrophic factor family ligands. RET regulates cell death/survival, balance and positional information. It orchestrates molecular cascades during intestinal, gut neuroendocrine, gut MALT and renal organogenesis, and it modulates cell adhesion by cleaving caspase in sympathetic neurons and mediates cell migration in an integrin (e.g., ITGB1 and ITGB3)-dependent manner. RET triggers apoptosis by intracellular caspase cleavage; it promotes survival and downregulates growth hormone production, but triggers apoptosis in absence of GDNF.

Molecular pathology
RET mutations are associated with  neuroendocrine cancers, which are characterised by defects in integrin-regulated cell migration.

RET

Abbrev. for rearranged during TRANSFECTION.

retinoscopy (ret) 

The determination of the refractive state of the eye by means of a retinoscope. Syn. skiascopy; shadow test. See chromoretinoscopy.
dynamic retinoscopy Retinoscopy performed with the patient fixating binocularly a near object such as a letter, a word, or a picture mounted on, or held close to, the retinoscope and wearing the distance correction. No working distance lens power is subtracted or added to the finding since the plane of regard is at the same distance as the retinoscope. Syn. book retinoscopy (this term is restricted to the case when the patient is reading a text); cognitive retinoscopy (when the patient fixates a single letter or reads some words); near point retinoscopy. See lag of accommodation; objective accommodation; MEM retinoscopy; Mohindra's technique of retinoscopy; static retinoscopy.
MEM retinoscopy A type of dynamic retinoscopy in which the retinoscope is held in the same plane as the near fixation target and lenses are interposed very briefly in front of one eye, while the other eye fixates the target. The aim of the method is to estimate the fundus reflex motion without disturbing the accommodative stance, that is, by leaving each lens in front of one eye for less than one second, until the neutral point is achieved. The results in non-presbyopic subjects generally show a lag of accommodation of 0 to +0.75 D. Note: MEM is an acronym of 'monocular estimate method'.
Mohindra's technique of retinoscopy Retinoscopy performed in a darkened room at 50 cm (20 inches) with the patient fixating the retinoscope light monocularly (the other eye being occluded). Distance retinoscopic refraction is derived by adding −1.00 D (to take into account the working distance and the state of accommodation in the dark) to the value found by near retinoscopy. The technique is used in paediatric optometry. Syn. monocular near retinoscopy. See resting state of accommodation; dynamic retinoscopy; MEM retinoscopy.
near point retinoscopy See dynamic retinoscopy; Mohindra's technique of.
static retinoscopy Retinoscopy performed with the patient fixating a target at distance or with accommodation paralysed.
References in periodicals archive ?
FIGURE 8 RECEPTOR TYROSINE KINASE INHIBITOR MARKET SHARE BY REGION, 2010 (%) 53
FIGURE 50 ASIAN MARKET FOR RECEPTOR TYROSINE KINASE INHIBITORS 2009-2016 ($
A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers -- combine them with inhibitors of the MEK/ERK signaling pathway.
The largest subfamily of receptor tyrosine kinases is the Eph family, which has 14 fully sequenced members.
BGB324 is a first-in-class, highly selective small molecule inhibitor of the Axl receptor tyrosine kinase.
Lenvatinib, discovered and developed by Eisai, is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFR), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor receptors (FGFR), the platelet-derived growth factor (PDGF) receptor PDGFR?
Tivantinib is an orally administered, selective inhibitor of MET, a receptor tyrosine kinase.
Using high throughput DNA sequencing, researchers conducted the first comprehensive DNA sequence analysis of the receptor tyrosine kinase gene family in glioblastomas, an aggressive form of brain cancer.
BLU-285 in GIST BLU-285 is a highly targeted drug that potently and selectively inhibits PDGFR[eth] D842V and KIT Exon 17 mutants, which are receptor tyrosine kinase mutants known to be key drivers in treatment-resistant and metastatic GIST.
Drug supply Sunitinib, an inhibitor of receptor tyrosine kinase (RTK), bound for Business Public Health Agency of Poniente Hospital.
ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase.
In this collection of 11 articles, contributors describe their work in PTKs in such areas as using PTKs as targets for cancer and other indications, targeting Src homology 2 domains in drug discovery, using P12-kinase inhibition as a target for therapeutic intervention, using an activated FLT3 receptor tyrosine kinase as a therapeutic target in leukemia and JAK kinases in leukemia, lymphomas and multiple myeloma, applying platelet-derived growth factor, using a targeted therapy for myelogenous leukemia, testing signal transduction inhibitors in animal models of cancer, and using phosphoproteomics in drug discovery and development.

Full browser ?